An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Table 2 US cost per hospitalization day for Grade 3/4 adverse events, symptomatic skeletal events, and end-of-life care

Event	US cost per hospitalization day
Diarrhea	$4134 (€3514)^a
Infection	$2422 (€2059)^a
Renal disorder	$2928 (€2489)^a
Cardiac disorder	$3282 (€2790)^a
Febrile neutropenia	$4685 (€3982)^a
Anemia	$6111 (€5194)^b
Thrombocytopenia	$5099 (€4334)^b
Hyponatremia	$5232 (€4447)^b
Pathological fracture	$6277 (€5335)^a
Spinal cord compression	$9276 (€7885)^a
End of life	$5939 (€5048)^c

Abbreviations: ICU intensive care unit, US United States
ICU costs were assumed to be part of the hospitalization costs
^aTo obtain the respective cost, hospitalization costs per event were divided by the length of stay or expected days of hospitalization (based on clinician input) (Supplementary Appendix 5)
^bAdapted from Bilir et al. (2016) [28]
^cAdapted from Wilson et al. (2014) [27]

ISSN: 1472-6963